MedTrace Logo

A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

NCT00814606 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-07-01

No results posted yet for this study

Summary

This study seeks to evaluate the safety and efficacy of taking fluvastatin along with peginterferon alfa in previous partial responders with genotype 1 HCV.

Conditions

  • Hepatitis C
  • Hepatitis C Virus

Interventions

DRUG

Fluvastatin

Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily

DRUG

Peginterferon alfa2a

180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)

DRUG

ribavirin

1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • K Gautham Reddy, MD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-10-31
Completion
2010-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00814606 on ClinicalTrials.gov